MLM Share Price

Open 0.46 Change Price %
High 0.46 1 Day 0.00 0.00
Low 0.46 1 Week 0.00 0.00
Close 0.46 1 Month -0.02 -4.17
Volume 1804775 1 Year 0.11 31.43
52 Week High 0.64
52 Week Low 0.29
MLM Important Levels
Resistance 2 0.46
Resistance 1 0.46
Pivot 0.46
Support 1 0.46
Support 2 0.46
BIT Italy Most Active Stocks
ISP 2.67 0.00%
SPM 0.40 0.00%
SPM 0.40 0.00%
TIT 0.82 0.00%
PMI 0.36 0.00%
PMI 0.36 0.00%
JUVE 0.85 3.66%
JUVE 0.85 3.66%
ENEL 4.36 -0.91%
RN 0.04 0.00%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
EEMS 0.12 9.09%
NR 0.27 8.00%
NR 0.27 8.00%
NR 0.27 8.00%
VRW 1.13 6.60%
VRW 1.13 6.60%
More..
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
TFI 0.91 -4.21%
TFI 0.91 -4.21%
TFI 0.91 -4.21%
CRG 0.25 -3.85%
CRG 0.25 -3.85%
CRG 0.25 -3.85%
SSL 0.75 -3.85%
SSL 0.75 -3.85%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 3
As on 28th Apr 2017 MLM Share Price closed @ 0.46 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.41 & Buy for SHORT-TERM with Stoploss of 0.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for April
1st Target up-side 0.52
2nd Target up-side 0.54
3rd Target up-side 0.57
1st Target down-side 0.44
2nd Target down-side 0.42
3rd Target down-side 0.39
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
MLM Latest News
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.